Pasithea Enterprise Value from 2010 to 2024

KTTAW Stock

USD 0.02 0 11.11%

Pasithea Therapeutics Enterprise Value yearly trend continues to be fairly stable with very little volatility. Enterprise Value is likely to outpace its year average in 2024. Enterprise Value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. View All Fundamentals

Enterprise Value

First Reported

2010-12-31

Previous Quarter

-18.4 M

Current Value

-17.5 M

Quarterly Volatility

29.7 M

Credit Downgrade

Yuan Drop

Covid

Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 680.9 K, Other Operating Expenses of 9.9 M or Total Operating Expenses of 9.8 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 0.0 or PTB Ratio of 0.38. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.

Check out the analysis of Pasithea Therapeutics Correlation against competitors.

Latest Pasithea Therapeutics' Enterprise Value Growth Pattern

Below is the plot of the Enterprise Value of Pasithea Therapeutics Corp over the last few years. Enterprise Value (or EV) is usually referred to as Pasithea Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Pasithea Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of Pasithea Therapeutics value than its market capitalization because it takes into account all of Pasithea Therapeutics Corp existing debt. It is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. Pasithea Therapeutics' Enterprise Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Enterprise Value

Timeline

Pasithea Enterprise Value Regression Statistics

	Arithmetic Mean	31,514,732
	Geometric Mean	36,160,988
	Coefficient Of Variation	94.27
	Mean Deviation	25,362,450
	Median	48,807,312
	Standard Deviation	29,709,658
	Sample Variance	882.7T
	Range	67.2M
	R-Value	(0.77)
	Mean Square Error	384.3T
	R-Squared	0.60
	Significance	0.0007
	Slope	(5,127,553)
	Total Sum of Squares	12357.3T

Pasithea Enterprise Value History

	2024	-17.5 M
	2023	-18.4 M
	2022	-16 M
	2021	-12.2 M

Other Fundumenentals of Pasithea Therapeutics

	Enterprise Value Over E B I T D A
	Enterprise Value Multiple

Pasithea Therapeutics Enterprise Value component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Current Deferred Revenue	Net Receivables	Short Term Debt	Intangible Assets
Total Assets		1.0	-0.96	-0.63	0.68	0.91	1.0	0.99	-0.25	0.98	-0.25	-0.42	-0.42	-0.41	-0.41
Total Stockholder Equity	1.0		-0.97	-0.61	0.67	0.9	1.0	0.99	-0.23	0.98	-0.23	-0.41	-0.4	-0.39	-0.4
Net Debt	-0.96	-0.97		0.42	-0.48	-0.8	-0.97	-0.98	0.05	-0.99	0.05	0.22	0.22	0.22	0.2
Retained Earnings	-0.63	-0.61	0.42		-1.0	-0.86	-0.61	-0.52	0.85	-0.48	0.85	0.91	0.92	0.92	0.79
Accounts Payable	0.68	0.67	-0.48	-1.0		0.88	0.67	0.58	-0.83	0.55	-0.83	-0.91	-0.91	-0.9	-0.81
Total Liab	0.91	0.9	-0.8	-0.86	0.88		0.9	0.84	-0.5	0.81	-0.5	-0.64	-0.65	-0.66	-0.51
Net Invested Capital	1.0	1.0	-0.97	-0.61	0.67	0.9		0.99	-0.23	0.98	-0.23	-0.41	-0.4	-0.39	-0.4
Total Current Assets	0.99	0.99	-0.98	-0.52	0.58	0.84	0.99		-0.16	1.0	-0.16	-0.34	-0.33	-0.32	-0.36
Capital Stock	-0.25	-0.23	0.05	0.85	-0.83	-0.5	-0.23	-0.16		-0.13	1.0	0.98	0.98	0.98	0.86
Net Working Capital	0.98	0.98	-0.99	-0.48	0.55	0.81	0.98	1.0	-0.13		-0.13	-0.31	-0.3	-0.28	-0.34
Common Stock	-0.25	-0.23	0.05	0.85	-0.83	-0.5	-0.23	-0.16	1.0	-0.13		0.98	0.98	0.98	0.86
Current Deferred Revenue	-0.42	-0.41	0.22	0.91	-0.91	-0.64	-0.41	-0.34	0.98	-0.31	0.98		1.0	0.98	0.91
Net Receivables	-0.42	-0.4	0.22	0.92	-0.91	-0.65	-0.4	-0.33	0.98	-0.3	0.98	1.0		0.99	0.88
Short Term Debt	-0.41	-0.39	0.22	0.92	-0.9	-0.66	-0.39	-0.32	0.98	-0.28	0.98	0.98	0.99		0.82
Intangible Assets	-0.41	-0.4	0.2	0.79	-0.81	-0.51	-0.4	-0.36	0.86	-0.34	0.86	0.91	0.88	0.82

Click cells to compare fundamentals

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' Enterprise Value, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Enterprise Value Over EBITDA	0.45	0.43
Enterprise Value Multiple	0.45	0.43
Enterprise Value	-18.4 M	-17.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC